Age at time of treatment: 26 – 35
Injury Level: T5, T6
Treatment Received:Â Stem Cells, Epidural Stimulation
Location of Treatment: Thailand
Time between injury and treatment: 2 – 5 years
Date of Surgery: 02/04/2018
Date of Discharge: 05/05/2018
Patient sustained a complete T5-6 fracture-dislocation spinal cord injury in 2014 with subsequent partial spinal cord transection and myelomalacia (spinal cord softening). Patient has minimal motor or sensory function below injury level and is suffering from neurogenic bladder and bowel. Patient does not experience severe spasms or spasticity and does not suffer from neuropathic pain. Patient is independent in his daily activities.
N/A
Patient sustained a complete T5-6 fracture-dislocation spinal cord injury in 2014 with subsequent partial spinal cord transection and myelomalacia (spinal cord softening). Patient has minimal motor or sensory function below injury level and is suffering from neurogenic bladder and bowel. Patient does not experience severe spasms or spasticity and does not suffer from neuropathic pain. Patient is independent in his daily activities.
After a spinal MRI scan, EMG, and comprehensive blood work, patient underwent laminectomy and implantation of the epidural stimulation device on April 2, 2018. The device is the ‘Medtronic Restore Advance 16-electrode MRI Compatible Device’. The surgery was completed without significant adverse events and no serious complications were reported during the postoperative hospital stay.
After epidural stimulation surgery, patient received 88 mapping sessions and 28 physical therapy sessions. Patient also received 120 million stem cells: 40 million Mesenchymal Stem Cells (MSCs) and 80 million Amniotic Fluid Stem Cells (hAFSCs) through one IV injection and two lumbar puncture injections, respectively. All three applications went well without adverse effects and no short-term or acute complications have been reported.
Device mapping and therapy were carried out after surgery for 35 days, then patient was discharged.
Patient is paraplegic with normal upper limb function (fine motor skills), and does not experience spasms or spasticity, therefore 8 of 11 motor function areas were measured. Motor function improved in 8 out of 8 targeted areas when the epidural stimulation device was switched on.
Patient does not suffer from neuropathic pain, therefore 3 of 4 sensory function areas were measured. Patient has not experienced any changes in the three measured sensory function areas, but more feedback will be collected after 3 months to note any improvements made by stem cell treatment. Overall, improvements were observed in 8 out of 11 targeted motor and sensory function areas
epiduralstimulationnow.com is owned by Verita Neuro Pte. Ltd. Verita Neuro provides access to progressive, responsible healthcare to increase the quality of life. Verita Neuro partners with leading-edge, next-generation treatment providers, unique products and services, that are integrative, safe and effective. Verita Neuro is not a treatment provider.
All medical treatments have varied outcomes. Results from the treatments will vary from patient to patient. All examples of what has been achieved by others should not be taken as typical or in any way a guarantee or projection of what any individual can expect from treatment.